Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLS007
MIFTS: 57

Plasmodium Falciparum Malaria

Categories: Infectious diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Plasmodium Falciparum Malaria

About this section

MalaCards integrated aliases for Plasmodium Falciparum Malaria:

Name: Plasmodium Falciparum Malaria 12 15
Malaria, Falciparum 44 73
Malaria Fever, Subtertian 12
Malignant Tertian Fever 12
Falciparum Malaria 12
Malaria Falciparum 55

Classifications:

MalaCards categories:
Global: Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:14067
ICD10 33 B50 B50.9 B50.0
ICD9CM 35 084.0
MeSH 44 D016778
NCIt 50 C34798
UMLS 73 C0024535
Sources

Summaries for Plasmodium Falciparum Malaria

About this section
Disease Ontology : 12 A malaria described as a severe form of the disease caused by a parasite Plasmodium falciparum, which is marked by irrregular recurrence of paroxysms and prolonged or continuous fever.

MalaCards based summary : Plasmodium Falciparum Malaria, also known as malaria, falciparum, is related to schistosomiasis and q fever. An important gene associated with Plasmodium Falciparum Malaria is CR1 (Complement C3b/C4b Receptor 1 (Knops Blood Group)), and among its related pathways/superpathways are Innate Immune System and Allograft rejection. The drugs Amodiaquine and Artemether have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and liver, and related phenotypes are hematopoietic system and cellular

Sources

Related Diseases for Plasmodium Falciparum Malaria

About this section

Diseases related to Plasmodium Falciparum Malaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 231)
# Related Disease Score Top Affiliating Genes
1 schistosomiasis 31.1 IFNG IL10 TNF
2 q fever 31.0 IFNG IL10 TNF
3 alpha-thalassemia 30.2 G6PD HBB HP
4 hemolytic anemia 29.8 CD55 G6PD HBB HP
5 plasmodium vivax malaria 29.4 G6PD ICAM1 IFNG IL10 SELE TNF
6 glomerulonephritis 28.9 CR1 ICAM1 MIF TLR9
7 dermatitis, atopic 27.8 ICAM1 IFNG IL10 IL18 SELE TLR9
8 asthma 27.1 CHIT1 ICAM1 IFNG IL10 IL18 SELE
9 malaria 24.1 CD36 CD55 CHIT1 CR1 DHFR FCGR2A
10 anemia, nonspherocytic hemolytic, due to g6pd deficiency 11.3
11 punctate inner choroidopathy 11.0 IL10 TNF
12 tropical endomyocardial fibrosis 10.9 IL10 TNF
13 hyperlucent lung 10.8 IFNG IL10
14 staphylococcal toxic shock syndrome 10.8 IFNG TNF
15 microscopic polyangiitis 10.8 IL10 TNF
16 multifocal choroiditis 10.8 IL10 TNF
17 systemic onset juvenile idiopathic arthritis 10.8 IL18 TNF
18 tungiasis 10.8 IL10 TNF
19 endomyocardial fibrosis 10.8 IL10 TNF
20 autoimmune myocarditis 10.8 IFNG TNF
21 clonorchiasis 10.7 IFNG IL10 TNF
22 primary systemic mycosis 10.7 IFNG IL10 TNF
23 intermediate uveitis 10.7 IFNG IL10 TNF
24 orofacial granulomatosis 10.7 IFNG IL10 TNF
25 transient hypogammaglobulinemia 10.7 IL10 TNF
26 eales disease 10.7 IFNG IL10 TNF
27 hemorrhagic fever 10.7 IFNG IL10 TNF
28 chronic graft versus host disease 10.7 CD36 IFNG IL10
29 spotted fever 10.7 IFNG IL10 TNF
30 hematopoietic stem cell transplantation 10.7 IFNG IL10 TNF
31 aseptic meningitis 10.7 IFNG IL10 TNF
32 mixed connective tissue disease 10.7 IFNG IL10 TNF
33 echinococcosis 10.7 IFNG IL10 TNF
34 reactive arthritis 10.7 IFNG IL10 TNF
35 brucellosis 10.7 IFNG IL10 TNF
36 leprosy 3 10.7 IFNG IL10 TNF
37 spondyloarthropathy 10.7 IFNG IL10 TNF
38 bronchiolitis obliterans 10.6 IFNG IL10 TNF
39 gastroenteritis 10.6 IFNG IL10 TNF
40 hemoglobinemia 10.6 HBB HP
41 pleural tuberculosis 10.6 IFNG IL18 TNF
42 primary progressive multiple sclerosis 10.6 ICAM1 IL10 TNF
43 chlamydia 10.6 IFNG IL10 TNF
44 rasmussen encephalitis 10.6 IFNG IL18 TNF
45 helicobacter pylori infection 10.6 IFNG IL10 TNF
46 erythema multiforme 10.6 ICAM1 IFNG TNF
47 toxic shock syndrome 10.6 IFNG IL10 TNF
48 graft-versus-host disease 10.6 IFNG IL10 TNF
49 trichosporonosis 10.6 IFNG TNF
50 pulmonary edema 10.6 ICAM1 IL10 TNF

Graphical network of the top 20 diseases related to Plasmodium Falciparum Malaria:



Diseases related to Plasmodium Falciparum Malaria
Sources

Symptoms & Phenotypes for Plasmodium Falciparum Malaria

About this section

MGI Mouse Phenotypes related to Plasmodium Falciparum Malaria:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.28 MIF SELE TLR9 TNF CD36 CD55
2 cellular MP:0005384 10.27 SELE TLR9 TNF CD36 DHFR G6PD
3 cardiovascular system MP:0005385 10.22 CD36 DHFR G6PD HP ICAM1 IFNG
4 homeostasis/metabolism MP:0005376 10.18 CD36 DHFR G6PD MB MIF SELE
5 immune system MP:0005387 10.17 CD36 CD55 CHIT1 DHFR FCGR2A HP
6 digestive/alimentary MP:0005381 9.98 CD36 ICAM1 IFNG IL10 IL18 TLR9
7 mortality/aging MP:0010768 9.97 CD36 DHFR FCGR2A G6PD HP ICAM1
8 liver/biliary system MP:0005370 9.8 HP IFNG IL10 SELE TNF CD36
9 muscle MP:0005369 9.56 CD36 DHFR ICAM1 IFNG IL10 IL18
10 neoplasm MP:0002006 9.1 HP ICAM1 IFNG IL10 MIF TNF
Sources

Drugs & Therapeutics for Plasmodium Falciparum Malaria

About this section

Drugs for Plasmodium Falciparum Malaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amodiaquine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 86-42-0 2165
2
Artemether Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71963-77-4 119380 68911
3
Artesunate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 88495-63-0 6917864 5464098
4
Dihydroartemisinin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71939-50-9 6918483
5
Lumefantrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 82186-77-4 6437380
6
Mefloquine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53230-10-7 4046
7
Piperaquine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 4085-31-8 5079497
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
9
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 58-14-0 4993
10
Sulfadoxine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 2447-57-6 17134
11
Primaquine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90-34-6 4908
12
Nevirapine Approved Phase 4,Early Phase 1 129618-40-2 4463
13
chloroquine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 54-05-7 2719
14
Dapsone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 80-08-0 2955
15
Proguanil Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 500-92-5 4923
16
Atovaquone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 95233-18-4 74989
17
Quinine Approved Phase 4,Phase 3,Phase 2,Not Applicable 130-95-0 8549 3034034
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
19
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
20
Lactitol Investigational Phase 4,Phase 3,Phase 1,Not Applicable 585-86-4 3871
21
Chlorproguanil Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 537-21-3 151170 9571037
22 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Antimalarials Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Artemether-lumefantrine combination Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Artemisinine Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Artemisinins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Amodiaquine, artesunate drug combination Phase 4,Not Applicable
32 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Fanasil, pyrimethamine drug combination Phase 4,Phase 2,Phase 3,Not Applicable
36 Renal Agents Phase 4,Phase 2,Phase 3,Not Applicable
37 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
42 Chloroquine diphosphate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-63-5
43 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
45 Atovaquone, proguanil drug combination Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
46 Neuromuscular Agents Phase 4,Phase 3,Phase 2,Not Applicable
47 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Red Cinchona Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable
50
Azithromycin Approved Phase 2, Phase 3,Phase 3,Phase 1 83905-01-5 55185 447043

Interventional clinical trials:

(show top 50) (show all 317)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria Unknown status NCT00902811 Phase 4 AM(FDC);AM(LT);AL;DP;AA(FDC)
2 P. Falciparum Resistance to Artemisinin in Vietnam Unknown status NCT02604966 Phase 4 Artesunate (AS) group;DHA - PPQ group
3 Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period Unknown status NCT01038063 Phase 4 Artemether-lumefantrine combination
4 Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan Unknown status NCT01075945 Phase 4 Dihydroartemisinin- piperaquine;artemether- lumefantrine
5 Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate Unknown status NCT00238017 Phase 4 amodiaquine-artesunate versus amodiaquine
6 Assessment of Artesunate/Mefloquine in the Peruvian Amazon Unknown status NCT02084602 Phase 4 Artesunate;Mefloquine
7 Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics Unknown status NCT01944189 Phase 4
8 Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A Unknown status NCT01704508 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
9 Artemisinin-based Combination Therapy for Treatment of Plasmodium Falciparum Malaria in North Sumatera, Indonesia Completed NCT02325180 Phase 4 Dihydroartemisinin-Piperaquine;Artemether-lumefantrine
10 In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria Completed NCT02637128 Phase 4 artemether-lumefantrine (AL);artesunate-amodiaquine (ASAQ)
11 Efficacy and Safety of ASAQ and PD for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania Completed NCT03431714 Phase 4 Artesunate amodiaquine
12 Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria. Completed NCT02089841 Phase 4 Artemether-lumefantrine
13 Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso Completed NCT01017770 Phase 4 Artesunate-amodiaquine;Artemether-lumefantrine
14 Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria Completed NCT00529867 Phase 4 Artemether/lumefantrine tablets;Artemether/Lumefantrine suspension
15 Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Completed NCT00540410 Phase 4 Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination);Coartem® (arthemether+ lumefantrine)
16 Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in Tanzania Completed NCT00885287 Phase 4 Artemether-lumefantrine (AL)
17 Cohort Study in Uganda Comparing Artesunate + Amiodaquine (Coarsucam) Versus Artemether + Lumenfantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Completed NCT00699920 Phase 4 Coarsucam;Coartem
18 Safety and Efficacy Study of Artesunate and Mefloquin in Children With Uncomplicated Malaria Completed NCT00978172 Phase 4 artesunate and mefloquine
19 Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan Completed NCT01019408 Phase 4 Chloroquine
20 Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger Completed NCT01755559 Phase 4 Artesunate-amodiaquine;Dihydroartemisinin-piperaquine;Artemether-lumefantrine
21 Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi Completed NCT00164359 Phase 4 Amodiaquine plus artesunate;chlorproguanil-dapsone plus artesunate
22 Efficacy of Amodiaquine-artesunate in Children Aged 6-59 Months With Uncomplicated P. Falciparum Malaria Completed NCT00425763 Phase 4 AQAS
23 Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers Completed NCT00301015 Phase 4
24 CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi Completed NCT00125489 Phase 4 chloroquine sulfate;sulfadoxine/pyrimethamine
25 Efficacy and Safety of Artemisinin-based Combination Treatments in the Democratic Republic of the Congo Completed NCT02940756 Phase 4 artesunate-amodiaquine;artemether-lumefantrine;Dihydroartemisinine-piperaquine
26 Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO Completed NCT01930331 Phase 4 artemisinin/naphthoquine;dihydroartemisinin/piperaquine phosphate
27 Examination of ACT Implementation in a Vivax / Falciparum Co-endemic Area Completed NCT00935688 Phase 4
28 Tracking Resistance to Artemisinin (TRAC) Completed NCT01350856 Phase 4 Artesunate 2;Artesunate 4
29 Kintampo Trial of Combination Therapy for Malaria Completed NCT00119145 Phase 4 artesunate-amodiaquine;coartem;artesunate-lapdap
30 Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function Completed NCT00444106 Phase 4 Artesunate-mefloquine;Atovaquone-proguanil;Artemether-lumefantrine
31 Harmonized AS/MQ Efficacy Study - Thailand Completed NCT02052323 Phase 4 Artesunate/mefloquine (AS/MQ)
32 Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers Completed NCT00233337 Phase 4 Co-artemether
33 Treatment of Malaria With Quinine Plus Sulfadoxine-Pyrimethamine Completed NCT00167739 Phase 4 Quinine plus sulfadoxine-pyrimethamine
34 Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance Completed NCT00445796 Phase 4 Artesunate;Amodiaquine
35 Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire Completed NCT01023399 Phase 4 Artesunate + Amodiaquine
36 In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy Completed NCT01976780 Phase 4 Artesunate;Artemether Lumefantrine;Mefloquine
37 A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects Completed NCT00859807 Phase 4 Flavoquine®, Camoquin® Suspension;Flavoquine®, Camoquin® Suspension
38 Efficacy and Cost Effectiveness of Malaria Diagnosis Procedures and the Rational Use of ACT in Zanzibar Completed NCT00549003 Phase 4
39 Amodiaquine+Artesunate for Uncomplicated Malaria Treatment Completed NCT01213433 Phase 4 Artesunate-Amodiaquine
40 Parenteral Artesunate Compared to Quinine as a Cause of Late Anaemia in African Children With Malaria Completed NCT02092766 Phase 4 artesunate;quinine
41 Plasmodium Falciparum Artemisinin Resistance Vietnam Completed NCT01775592 Phase 4 Arterakin (DHA-PPQ)
42 Amodiaquine-Artesunate & Artemether-Lumefantrine Efficacy in Burkina Faso Completed NCT01697787 Phase 4 Amodiaquine-Artesunate;Artemether-lumefantrine
43 Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo Completed NCT02741024 Phase 4 Amodiaquine-Artesunate (ASAQ);Artemether-Lumefantrine (AL)
44 In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children Completed NCT02168569 Phase 4 Coartemâ„¢ (Artemether-lumefantrine combination);Coarsucamâ„¢ (Amodiaquine-artesunate combination)
45 Parasite Clearance Time and Time to Recurrent Infection Following Treatment With Artemether/Lumefantrine Completed NCT01998295 Phase 4 Artemether/lumefantrine
46 Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy Completed NCT00495508 Phase 4 Quinine;artemether / lumefantrine
47 In-Vivo Response of P. Falciparum to Antimalarial Treatment in HIV-Infected and HIV-Uninfected Adults Completed NCT00144352 Phase 4 sulfadoxine-pyrimethamine
48 ACT MALI: Treatment of Malaria Based on Combination Therapies Completed NCT00452907 Phase 4 Artesunate;Artesunate + Sulfadoxine-Pyrimethamine;arthemether + lumefantrine
49 Pharmacokinetic Study of Multi-dose Chloroquine Completed NCT01814423 Phase 4 Chloroquine-base 50 mg;Chloroquine-base 70 mg
50 A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh Completed NCT02389374 Phase 4 chloroquine;Artemether-lumefantrine combination;Primaquine;Primaquine

Search NIH Clinical Center for Plasmodium Falciparum Malaria

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: malaria, falciparum

Sources

Genetic Tests for Plasmodium Falciparum Malaria

About this section
Sources

Anatomical Context for Plasmodium Falciparum Malaria

About this section

MalaCards organs/tissues related to Plasmodium Falciparum Malaria:

41
Testes, T Cells, Liver, Skin, Neutrophil, Endothelial, Monocytes
Sources

Publications for Plasmodium Falciparum Malaria

About this section

Articles related to Plasmodium Falciparum Malaria:

(show top 50) (show all 772)
# Title Authors Year
1
Treatment for Uncomplicated Plasmodium falciparum Malaria in French Soldiers Deployed in Sub-Saharan Africa: Gaps Between Policy and Field Practice. ( 29425320 )
2018
2
Severe Plasmodium falciparum Malaria Treated With Investigational Artesunate in the United States. ( 29898630 )
2018
3
Efficacy and safety of artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Sudan: a systematic review and meta-analysis. ( 29534720 )
2018
4
Blackwater fever in a non-immune patient with Plasmodium falciparum malaria after intravenous artesunate. ( 29394389 )
2018
5
DSM265: a novel drug for single-dose cure of Plasmodium falciparum malaria. ( 29909070 )
2018
6
Etiology of Placental Plasmodium falciparum Malaria in African Women. ( 29579263 )
2018
7
Spatio-temporal distribution of PfMDR1 polymorphism among uncomplicated Plasmodium falciparum malaria cases along international border of north east India. ( 29842979 )
2018
8
Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger. ( 29370844 )
2018
9
Can the Therapeutically-rational Exchange (T-REX) of Glucose-6-phosphate Dehydrogenase Deficient Red Blood Cells Reduce Plasmodium falciparum Malaria Morbidity and Mortality? ( 29717302 )
2018
10
Efficacy and tolerability of artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria at two sentinel sites across CA'te da89Ivore ( 29717574 )
2018
11
Dihydroartemisinin-piperaquine treatment failure in uncomplicated Plasmodium falciparum malaria case imported from Ethiopia. ( 29980936 )
2018
12
Pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial. ( 29764419 )
2018
13
Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017. ( 29615039 )
2018
14
Posttreatment HRP2 Clearance in Patients with Uncomplicated Plasmodium falciparum Malaria. ( 29220497 )
2018
15
Sub-acute intestinal obstruction - a rare complication of Plasmodium falciparum malaria in an adult: a case report. ( 29966528 )
2018
16
Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme. ( 29703425 )
2018
17
Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa. ( 29347975 )
2018
18
Plasmodium falciparum malaria skews globin gene expression balance in in-vitro haematopoietic stem cell culture system: Its implications in malaria associated anemia. ( 29309785 )
2018
19
Kinetics of antibody responses to PfRH5-complex antigens in Ghanaian children with Plasmodium falciparum malaria. ( 29883485 )
2018
20
Epidemiological, Clinical, and Laboratory Evaluation of Plasmodium falciparum Malaria Cases Followed in Firat University Hospital: A 6-Year Retrospective Analysis. ( 29780012 )
2018
21
Multidrug-resistant Plasmodium falciparum malaria in the Greater Mekong subregion. ( 29398389 )
2018
22
A Case of Severe Plasmodium falciparum Malaria Co-Infected with HIV Improved with Exchange Transfusion. ( 29318993 )
2017
23
Severe Plasmodium falciparum malaria in the intensive care unit: A 6-year experience in Milano, Italy. ( 28554853 )
2017
24
Congenital Plasmodium falciparum Malaria in Washington, DC. ( 28077745 )
2017
25
AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial. ( 28916443 )
2017
26
Combating multidrug-resistant Plasmodium falciparum malaria. ( 28580606 )
2017
27
Assessment of Myocardial Function and Injury by Echocardiography and Cardiac Biomarkers in African Children With Severe Plasmodium falciparum Malaria. ( 29206727 )
2017
28
Elimination of Plasmodium falciparum malaria in Tajikistan. ( 28558764 )
2017
29
Phase 2a, Open-Label, 4-Escalating-Dose, Randomized Multicenter Study Evaluating the Safety and Activity of Ferroquine (SSR97193) Plus Artesunate, versus Amodiaquine Plus Artesunate, in African Adult Men with Uncomplicated Plasmodium falciparum Malaria. ( 28722611 )
2017
30
Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients With Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial. ( 28605472 )
2017
31
Molecular surveillance of chloroquine drug resistance markers (Pfcrt and Pfmdr1) among imported Plasmodium falciparum malaria in Qatar. ( 29125042 )
2017
32
Analysis of the Clinical Profile in Patients with Plasmodium falciparum Malaria and Its Association with Parasite Density. ( 28584457 )
2017
33
Longitudinal genomic surveillance of Plasmodium falciparum malaria parasites reveals complex genomic architecture of emerging artemisinin resistance. ( 28454557 )
2017
34
Effects of Aging on Parasite Biomass, Inflammation, Endothelial Activation, Microvascular Dysfunction and Disease Severity in Plasmodium knowlesi and Plasmodium falciparum Malaria. ( 28863470 )
2017
35
Obesity and Diabetes as Risk Factors for Severe Plasmodium falciparum Malaria: Results From a Swedish Nationwide Study. ( 28510633 )
2017
36
Associations between an IgG3 polymorphism in the binding domain for FcRn, transplacental transfer of malaria-specific IgG3, and protection against Plasmodium falciparum malaria during infancy: A birth cohort study in Benin. ( 28991911 )
2017
37
Inhibition of merozoite invasion and transient de-sequestration by sevuparin in humans with Plasmodium falciparum malaria. ( 29244851 )
2017
38
Association of CD40L gene polymorphism with severe Plasmodium falciparum malaria in Indian population. ( 28352049 )
2017
39
Evidence of non-Plasmodium falciparum malaria infection in KAcdougou, SAcnAcgal. ( 28049489 )
2017
40
Mapping sulphadoxine-pyrimethamine-resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa. ( 28785011 )
2017
41
Multicenter Pivotal Clinical Trial of Urine Malaria Test for Rapid Diagnosis of Plasmodium falciparum Malaria. ( 27847373 )
2017
42
Comparative study of clinical presentation and hematological indices in hospitalized sickle cell patients with severe Plasmodium falciparum malaria. ( 28927555 )
2017
43
Therapeutic plasma exchange in the treatment of complicated Plasmodium falciparum malaria: A case report. ( 28922459 )
2017
44
Therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Ethiopia: a systematic review and meta-analysis. ( 29137664 )
2017
45
Risk of drug resistance in Plasmodium falciparum malaria therapy-a systematic review and meta-analysis. ( 28028628 )
2017
46
Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study. ( 28566213 )
2017
47
Sustained High Cure Rate of Artemether-Lumefantrine against Uncomplicated Plasmodium falciparum Malaria after 8 Years of Its Wide-Scale Use in Bagamoyo District, Tanzania. ( 28829723 )
2017
48
Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in CA'te d'Ivoire. ( 28049523 )
2017
49
Expression of cleaved caspase-3 in renal tubular cells in Plasmodium falciparum malaria patients. ( 26729581 )
2017
50
Performance of a High-Sensitivity Rapid Diagnostic Test for Plasmodium falciparum Malaria in Asymptomatic Individuals from Uganda and Myanmar and Naive Human Challenge Infections. ( 28820709 )
2017
Sources

Variations for Plasmodium Falciparum Malaria

About this section
Sources

Expression for Plasmodium Falciparum Malaria

About this section
Search GEO for disease gene expression data for Plasmodium Falciparum Malaria.
Sources

Pathways for Plasmodium Falciparum Malaria

About this section

Pathways related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.76 CD36 CD55 CHIT1 CR1 FCGR2A HBB
2
Allograft rejection 1 37
Show member pathways
 12.82 CD55 ICAM1 IFNG IL10 IL18 TNF
3
Influenza A 37
Show member pathways
 12.72 ICAM1 IFNG IL18 TLR9 TNF
4
Regulation of IFNA signaling 66
Show member pathways
 12.56 IFNG IL10 IL18 TNF
5
Th17 cell differentiation 37
Show member pathways
 12.37 IFNG IL10 IL18 TNF
6
Folate Metabolism 1
Show member pathways
 12.28 DHFR HBB ICAM1 IFNG TNF
7
Th1 Differentiation Pathway 65
Show member pathways
 12.17 IFNG IL10 IL18 TLR9 TNF
8
Toxoplasmosis 37
Show member pathways
 12.15 CR1 FCGR2A IFNG IL10 TNF
9
Fluid shear stress and atherosclerosis 37
12.04 ICAM1 IFNG SELE TNF
10
Tuberculosis 37
11.95 CR1 FCGR2A IFNG IL10 IL18 TLR9
11
Spinal Cord Injury 1
11.91 FCGR2A ICAM1 IFNG MIF TNF
12
TNF signaling pathway 37
11.88 ICAM1 SELE TNF
13
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.87 CD36 FCGR2A IFNG IL10 TNF
14
Binding and Uptake of Ligands by Scavenger Receptors 66
Show member pathways
 11.86 CD36 HBB HP
15
Hematopoietic cell lineage 37
11.85 CD36 CD55 CR1 TNF
16
AGE-RAGE signaling pathway in diabetic complications 37
11.83 ICAM1 SELE TNF
17
Interleukin-4 and 13 signaling 66
11.82 CD36 ICAM1 IL10 IL18 TNF
18
Amoebiasis 37
11.81 IFNG IL10 TNF
19
Rheumatoid arthritis 37
11.81 ICAM1 IFNG IL18 TNF
20
Phagocytosis of Microbes 64
11.75 CR1 FCGR2A TLR9
21
Innate Lymphoid Cell Differentiation Pathways 65
11.74 IFNG IL10 IL18 TNF
22
Glucocorticoid receptor regulatory network 1
11.73 ICAM1 IFNG SELE
23
Dendritic Cells Developmental Lineage Pathway 65
11.69 IFNG IL10 TLR9 TNF
24
Staphylococcus aureus infection 37
11.55 FCGR2A ICAM1 IL10
25
Legionellosis 37
11.54 CR1 IL18 TNF
26
amb2 Integrin signaling 1
11.47 HP ICAM1 TNF
27
MSP-RON Signaling 64
11.47 IFNG IL18 TNF
28
Interleukin-10 signaling 66
11.45 ICAM1 IL10 IL18 TNF
29
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.45 ICAM1 IFNG MIF SELE TNF
30
Malaria 37
11.34 CD36 CR1 HBB ICAM1 IFNG IL10
31
Development and heterogeneity of the ILC family 1
11.27 IFNG IL18 TNF
32
Cytokines and Inflammatory Response 1
11.24 IFNG IL10 TNF
33
IL1 and megakaryocytes in obesity 1
11.15 ICAM1 IFNG IL18
34
LDL Oxidation in Atherogenesis 64
10.89 CD36 ICAM1 TNF
35
African trypanosomiasis 37
10.77 HBB ICAM1 IFNG IL10 IL18 SELE
Sources

GO Terms for Plasmodium Falciparum Malaria

About this section

Cellular components related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 CD55 CHIT1 HBB HP IFNG IL10
2 cell surface GO:0009986 9.73 CD36 CD55 CR1 ICAM1 MIF TNF
3 secretory granule membrane GO:0030667 9.63 CD55 CR1 FCGR2A
4 tertiary granule lumen GO:1904724 9.58 CHIT1 HBB HP
5 endocytic vesicle lumen GO:0071682 9.43 HBB HP
6 extracellular space GO:0005615 9.4 CD36 CHIT1 HBB HP ICAM1 IFNG
7 membrane raft GO:0045121 9.35 CD36 CD55 ICAM1 SELE TNF
8 haptoglobin-hemoglobin complex GO:0031838 9.32 HBB HP
9 extracellular exosome GO:0070062 10.07 CD55 CR1 FCGR2A G6PD HBB HP

Biological processes related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

(show all 45)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 CD36 ICAM1 MIF TNF
2 negative regulation of gene expression GO:0010629 9.96 CD36 IFNG MIF TNF
3 defense response to bacterium GO:0042742 9.96 HP IL10 TLR9 TNF
4 leukocyte migration GO:0050900 9.95 ICAM1 MIF SELE TNF
5 cytokine-mediated signaling pathway GO:0019221 9.92 CD36 ICAM1 IL10 IL18 TNF
6 response to organic substance GO:0010033 9.86 HP IL10 TNF
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.85 CD36 ICAM1 MIF
8 viral entry into host cell GO:0046718 9.85 CD55 CR1 ICAM1
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 CD36 ICAM1 TLR9 TNF
10 immune response GO:0006955 9.85 CD36 CHIT1 IFNG IL10 IL18 TNF
11 cellular response to lipopolysaccharide GO:0071222 9.84 CD36 ICAM1 IL10 TNF
12 response to hydrogen peroxide GO:0042542 9.79 HBB HP MB
13 positive regulation of cell death GO:0010942 9.77 CD36 HBB HP
14 positive regulation of interleukin-6 production GO:0032755 9.77 CD36 TLR9 TNF
15 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.75 IL18 TLR9 TNF
16 interleukin-12-mediated signaling pathway GO:0035722 9.74 IFNG IL10 MIF
17 positive regulation of tumor necrosis factor production GO:0032760 9.73 CD36 MIF TLR9
18 inflammatory response GO:0006954 9.73 IL10 IL18 MIF SELE TLR9 TNF
19 leukocyte tethering or rolling GO:0050901 9.7 SELE TNF
20 oxygen transport GO:0015671 9.69 HBB MB
21 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.69 IFNG TNF
22 regulation of regulatory T cell differentiation GO:0045589 9.69 CR1 IFNG
23 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.68 CD36 IL18
24 response to molecule of bacterial origin GO:0002237 9.68 IL10 TLR9
25 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.67 IL10 TNF
26 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.67 IL18 TLR9
27 endothelial cell apoptotic process GO:0072577 9.65 IL10 TNF
28 positive regulation of cytokine secretion GO:0050715 9.65 IL10 MIF TNF
29 regulation of removal of superoxide radicals GO:2000121 9.64 CD36 DHFR
30 negative regulation of cytokine secretion involved in immune response GO:0002740 9.63 IL10 TNF
31 type 2 immune response GO:0042092 9.63 IL10 IL18
32 negative regulation of interleukin-6 production GO:0032715 9.63 IL10 TLR9 TNF
33 negative regulation of interleukin-8 production GO:0032717 9.62 IL10 TLR9
34 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.62 ICAM1 TNF
35 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.58 MIF TNF
36 neutrophil degranulation GO:0043312 9.56 CD36 CD55 CHIT1 CR1 FCGR2A HBB
37 receptor biosynthetic process GO:0032800 9.51 IL10 TNF
38 positive regulation of interleukin-12 production GO:0032735 9.5 CD36 IFNG TLR9
39 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 IFNG TNF
40 positive regulation of blood microparticle formation GO:2000334 9.43 CD36 TNF
41 positive regulation of vitamin D biosynthetic process GO:0060557 9.4 IFNG TNF
42 negative regulation of growth of symbiont in host GO:0044130 9.33 CD36 IL10 TNF
43 positive regulation of nitric oxide biosynthetic process GO:0045429 9.02 CD36 HBB ICAM1 IFNG TNF
44 regulation of signaling receptor activity GO:0010469 10.04 IFNG IL10 IL18 MIF TNF
45 positive regulation of gene expression GO:0010628 10 CD36 IFNG IL18 TLR9 TNF

Molecular functions related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.33 CD55 CR1 ICAM1
2 oxygen carrier activity GO:0005344 9.26 HBB MB
3 cytokine activity GO:0005125 9.02 IFNG IL10 IL18 MIF TNF
4 hemoglobin binding GO:0030492 8.96 HBB HP
Sources

Sources for Plasmodium Falciparum Malaria

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....